The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development
- PMID: 17691956
- DOI: 10.2174/092986707781389619
The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development
Abstract
Phosphodiesterases (PDE) are a class of proteins whose most relevant biological activity concerns the modulation of intracellular levels of cyclic nucleotides, e.g., cGMP and cAMP. PDE isoenzyme 5 (PDE5) is specifically involved in cGMP inactivation in the smooth muscle cell. Chemical inhibition of PDE5 by sildenafil, tadalafil or vardenafil recently became a valid therapeutic option aimed at overexpressing the molecular pathway originated from nitric oxide and expressed via increased cell cGMP availability. Based on the optimal tolerability and proven efficacy in various human disorders, EMEA and FDA have approved PDE5 inhibition as an efficient therapy in some cardiovascular, pulmonary and vascular diseases. More specifically, PDE5 inhibition appears successful for the treatment of idiopathic arterial pulmonary hypertension. Furthermore, PDE5 inhibition resulted in important protective effects in the myocardium, i.e., antyhypertrophic and antiapoptic, as well as vascular functions, i.e., increased tolerance to ischemia/reperfusion injury and improved endothelial function, thereby implying a potential usefulness in the treatment of patients with heart failure and coronary artery disease. Evidence currently available for considering PDE5-inhibition an additional opportunity in the treatment of common cardiopulmonary disorders is here provided.
Similar articles
-
Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation.J Neurosci. 2003 Jul 23;23(16):6452-9. doi: 10.1523/JNEUROSCI.23-16-06452.2003. J Neurosci. 2003. PMID: 12878685 Free PMC article.
-
In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.Urol Res. 2007 Feb;35(1):49-54. doi: 10.1007/s00240-006-0073-1. Epub 2006 Nov 11. Urol Res. 2007. PMID: 17102958
-
High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.Biochem Biophys Res Commun. 2005 Sep 2;334(3):930-8. doi: 10.1016/j.bbrc.2005.06.183. Biochem Biophys Res Commun. 2005. PMID: 16023993
-
The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels.Curr Top Med Chem. 2007;7(4):437-54. doi: 10.2174/156802607779941198. Curr Top Med Chem. 2007. PMID: 17305584 Review.
-
Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.Expert Rev Cardiovasc Ther. 2006 May;4(3):293-300. doi: 10.1586/14779072.4.3.293. Expert Rev Cardiovasc Ther. 2006. PMID: 16716091 Review.
Cited by
-
Nitric Oxide-cGMP Pathway Modulation in an Experimental Model of Hypoxic Pulmonary Hypertension.J Cardiovasc Pharmacol Ther. 2021 Nov;26(6):665-676. doi: 10.1177/10742484211014162. Epub 2021 May 8. J Cardiovasc Pharmacol Ther. 2021. PMID: 33969747 Free PMC article.
-
The effect of sildenafil on retinal blood velocity in healthy subjects.Eye Vis (Lond). 2018 Dec 5;5:30. doi: 10.1186/s40662-018-0125-y. eCollection 2018. Eye Vis (Lond). 2018. PMID: 30534576 Free PMC article.
-
Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.Pharmacol Ther. 2009 Jun;122(3):216-38. doi: 10.1016/j.pharmthera.2009.02.009. Epub 2009 Mar 21. Pharmacol Ther. 2009. PMID: 19306895 Free PMC article. Review.
-
Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets.Signal Transduct Target Ther. 2023 Nov 20;8(1):431. doi: 10.1038/s41392-023-01652-9. Signal Transduct Target Ther. 2023. PMID: 37981648 Free PMC article. Review.
-
Sildenafil attenuates hypoxic pulmonary remodelling by inhibiting bone marrow progenitor cells.J Cell Mol Med. 2017 May;21(5):871-880. doi: 10.1111/jcmm.13026. Epub 2016 Nov 18. J Cell Mol Med. 2017. PMID: 27860185 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical